tirzepatide effects on heart Frontiers Impact of Obesity Severity on

Key advances In the SURMOUNT-1 trial for obesity, adults with overweight or obesity without type 2 diabetes mellitus achieved placebo-subtracted weight loss of up to 20% after 72 weeks of the GLP1GIP receptor co-agonist tirzepatide, with a similar safety profile to high-dose semaglutide 5

Wegovy or compounded semaglutide should be used as part of a medical weight loss program alongside a reduced-calorie diet and increased physical activity

Semaglutide, in both compounded and brand-name forms, typically requires only a weekly injection, while Saxenda is a daily injection

Semaglutide for weight management: Results from the STEP 1 trial